1. Scrip
  2. >>Rare Diseases

Citius Aims To Use Prior Experience With CTCL Drug To Its Commercial Advantage

 
• By Alaric DeArment

The company announced positive data for I/Ontak, a reformulated version of the cutaneous T-cell lymphoma drug Ontak and aims to submit for approval later in 2022.

Citius announced results of its Phase III trial of I/Ontak in cutaneous T-cell lymphoma • Source: Alamy

Citius Pharmaceuticals, Inc. is gearing up to reintroduce a drug for cutaneous T-cell lymphoma (CTCL) onto the market as it prepares to submit new Phase III data for I/Ontak (denileukin diftitox) to the US Food and Drug Administration. The company hopes to benefit from physicians’ prior experience and familiarity with an earlier version of the treatment.

I/Ontak is a recombinant fusion protein combining the interleukin-2 receptor binding domain with diphtheria toxin fragments. It’s a reformulated version...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

More from Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.